FDA has specifically flagged concerns with compounded injectable GLP-1 products, including: Nausea, vomiting, diarrhea, abdominal pain, and constipation Excessive dosing tied to titration mistakes, some serious enough to require hospitalization Concentration, measurement, labeling, and dosing considerations a mass-manufactured branded pen doesn't have in the same way A licensed provider needs to review your full medical history, current medications, and complete medication-specific risk information with you before treatment starts - this section is a prompt to have that conversation, not a substitute for it
Higher doses have been shown to bring more nausea 1 , but again, this typically eases as the body adjusts to the dose
Additive mechanisms: central activation of GLP-1R / GIPR hypothalamic satiety circuits, slowed gastric emptying, amplified glucose-dependent insulin secretion, direct adipocyte lipolysis via GCGR, brown thermogenesis via UCP1, and increased hepatic lipid oxidation
The 250+ synthesis steps include 17 distinct enzymatic reactions, each requiring separate purification
Problems with specific vendors often surface in forums before becoming widely known
The Eating Disorder Examination Questionnaire (EDE-Q) (Calugi et al., 2017) is also recommended for screening, as it assesses cognitive aspectssuch as the overvaluation of shape and weight, where individuals judge themselves predominantly or even exclusively in term on their shape, weight, and control over themand behavioral symptoms, including binge eating, self-induced vomiting, laxative/diuretic misuse, excessive exercise, and dietary restraint
